转移性非小细胞肺癌-话题@MedSci

#转移性非小细胞肺癌#

41篇内容 | 2111人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1472010, encodeId=d99e14e2010cf, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存, objectType=article, longId=194157, objectId=c3b319415e0d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3b319415e0d, replyNumber=0, likeNumber=53, createdTime=2020-05-16, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3b319415e0d, moduleTitle=CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3b319415e0d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1472009, encodeId=85a114e200976, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=CheckMate-227 三年随访数据证实：欧狄沃（纳武利尤单抗）联合伊匹木单抗为一线转移性非小细胞肺癌患者带来持久且长期的生存获益, objectType=article, longId=194156, objectId=071f1941562d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=071f1941562d, replyNumber=0, likeNumber=65, createdTime=2020-05-16, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=071f1941562d, moduleTitle=CheckMate-227 三年随访数据证实：欧狄沃（纳武利尤单抗）联合伊匹木单抗为一线转移性非小细胞肺癌患者带来持久且长期的生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=071f1941562d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1472008, encodeId=a8f814e20082e, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=FDA加速批准诺华的MET抑制剂Tabrecta，用于治疗METex14突变的转移性非小细胞肺癌, objectType=article, longId=193801, objectId=4a9d19380176, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a9d19380176, replyNumber=0, likeNumber=66, createdTime=2020-05-10, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a9d19380176, moduleTitle=FDA加速批准诺华的MET抑制剂Tabrecta，用于治疗METex14突变的转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a9d19380176)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1472007, encodeId=ab7214e2007bb, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗, objectType=article, longId=188797, objectId=3aed188e972f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3aed188e972f, replyNumber=0, likeNumber=49, createdTime=2020-02-27, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3aed188e972f, moduleTitle=武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3aed188e972f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1472006, encodeId=9a1f14e20069a, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=2018 AIOM指南：转移性非小细胞肺癌的治疗, objectType=article, longId=175056, objectId=84b31e505636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b31e505636, replyNumber=0, likeNumber=62, createdTime=2019-07-10, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b31e505636, moduleTitle=2018 AIOM指南：转移性非小细胞肺癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b31e505636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1472005, encodeId=006314e2005a8, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌, objectType=article, longId=165339, objectId=4a3216533980, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a3216533980, replyNumber=0, likeNumber=75, createdTime=2019-05-05, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a3216533980, moduleTitle=NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a3216533980)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1472004, encodeId=8c1b14e2004fa, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=拜耳公布larotrectinib治疗NTRK基因融合阳性转移性非小细胞肺癌患者的亚组分析结果, objectType=article, longId=164175, objectId=36571641e5d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36571641e5d2, replyNumber=0, likeNumber=71, createdTime=2019-04-14, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36571641e5d2, moduleTitle=拜耳公布larotrectinib治疗NTRK基因融合阳性转移性非小细胞肺癌患者的亚组分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36571641e5d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1472003, encodeId=ff7814e20034c, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=2019 加拿大共识：渐进性，假进行性和寡转移性非小细胞肺癌, objectType=article, longId=163209, objectId=720d1632097e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=720d1632097e, replyNumber=0, likeNumber=45, createdTime=2019-03-30, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=720d1632097e, moduleTitle=2019 加拿大共识：渐进性，假进行性和寡转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=720d1632097e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1472002, encodeId=cdec14e200246, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点, objectType=article, longId=162242, objectId=fef6162242d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fef6162242d9, replyNumber=0, likeNumber=65, createdTime=2019-03-14, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fef6162242d9, moduleTitle=Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fef6162242d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1472001, encodeId=b56914e200107, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=CLIN CANCER RES：T-DM1治疗HER2过表达转移性非小细胞肺癌, objectType=article, longId=158545, objectId=4a0315854589, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a0315854589, replyNumber=0, likeNumber=63, createdTime=2019-01-22, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a0315854589, moduleTitle=CLIN CANCER RES：T-DM1治疗HER2过表达转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a0315854589)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1472000, encodeId=5e6f14e2000dc, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=2018 ESMO临床实践指南：转移性非小细胞肺癌的诊断，治疗和随访, objectType=article, longId=150607, objectId=96e915060e0f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96e915060e0f, replyNumber=0, likeNumber=61, createdTime=2018-10-10, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96e915060e0f, moduleTitle=2018 ESMO临床实践指南：转移性非小细胞肺癌的诊断，治疗和随访, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96e915060e0f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1471999, encodeId=d2e114e1999e9, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=美国FDA批准VIZIMPRO用于EGFR突变的转移性非小细胞肺癌的一线治疗, objectType=article, longId=149975, objectId=90091499e58a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90091499e58a, replyNumber=0, likeNumber=75, createdTime=2018-09-30, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90091499e58a, moduleTitle=美国FDA批准VIZIMPRO用于EGFR突变的转移性非小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90091499e58a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1471998, encodeId=8abe14e1998e0, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=Lancet oncol：ALT-803（IL-15强激动剂）联合nivolumab用于转移性非小细胞肺癌安全性可耐受, objectType=article, longId=134404, objectId=edd7134404aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edd7134404aa, replyNumber=0, likeNumber=63, createdTime=2018-04-08, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edd7134404aa, moduleTitle=Lancet oncol：ALT-803（IL-15强激动剂）联合nivolumab用于转移性非小细胞肺癌安全性可耐受, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edd7134404aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1471997, encodeId=5be714e19975d, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=ANN ONCOL：反应程度与接受靶向或免疫治疗的转移性非小细胞肺癌患者预后的关系, objectType=article, longId=119390, objectId=30441193903e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30441193903e, replyNumber=0, likeNumber=54, createdTime=2017-11-11, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30441193903e, moduleTitle=ANN ONCOL：反应程度与接受靶向或免疫治疗的转移性非小细胞肺癌患者预后的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30441193903e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1471996, encodeId=1f1114e19969a, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=Front Pharmacol：在铂类治疗的转移性非小细胞肺癌患者中添加中药，能提高患者生活质量, objectType=article, longId=108615, objectId=85c810861552, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85c810861552, replyNumber=0, likeNumber=58, createdTime=2017-08-13, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85c810861552, moduleTitle=Front Pharmacol：在铂类治疗的转移性非小细胞肺癌患者中添加中药，能提高患者生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85c810861552)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1471995, encodeId=f1ab14e1995f7, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=JAMA Oncol：转移性非小细胞肺癌免疫检查点抑制剂、靶向治疗和常规治疗的里程碑分析, objectType=article, longId=102430, objectId=a303102430e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a303102430e0, replyNumber=0, likeNumber=77, createdTime=2017-06-21, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a303102430e0, moduleTitle=JAMA Oncol：转移性非小细胞肺癌免疫检查点抑制剂、靶向治疗和常规治疗的里程碑分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a303102430e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1471994, encodeId=c33514e199454, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=2016ESMO临床实践指南——转移性非小细胞肺癌的诊断、治疗和随访发布, objectType=article, longId=78694, objectId=ac50e8694d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac50e8694d5, replyNumber=0, likeNumber=41, createdTime=2016-09-29, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac50e8694d5, moduleTitle=2016ESMO临床实践指南——转移性非小细胞肺癌的诊断、治疗和随访发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac50e8694d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1471993, encodeId=876414e1993f6, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=招募患者：Nivolumab注射液治疗晚期或转移性非小细胞肺癌的临床试验, objectType=article, longId=61206, objectId=33146120623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33146120623, replyNumber=0, likeNumber=89, createdTime=2015-12-29, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33146120623, moduleTitle=招募患者：Nivolumab注射液治疗晚期或转移性非小细胞肺癌的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33146120623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1471992, encodeId=d4bd14e199252, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=招募患者：AZD9291治疗局部晚期或转移性非小细胞肺癌的开放、单臂临床研究, objectType=article, longId=56013, objectId=e6a1560130a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6a1560130a, replyNumber=0, likeNumber=53, createdTime=2015-09-11, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6a1560130a, moduleTitle=招募患者：AZD9291治疗局部晚期或转移性非小细胞肺癌的开放、单臂临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6a1560130a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1471991, encodeId=864814e19917b, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, objectTitle=Cancer：转移性非小细胞肺癌化疗治疗模式, objectType=article, longId=50054, objectId=99e35005437, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99e35005437, replyNumber=0, likeNumber=65, createdTime=2015-05-01, rootId=0, userName=anan, userId=14b77195705, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99e35005437, moduleTitle=Cancer：转移性非小细胞肺癌化疗治疗模式, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99e35005437)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性非小细胞肺癌

2020-05-29

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存

2020-05-16

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

CheckMate-227 三年随访数据证实：欧狄沃（纳武利尤单抗）联合伊匹木单抗为一线转移性非小细胞肺癌患者带来持久且长期的生存获益

2020-05-16

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

FDA加速批准诺华的MET抑制剂Tabrecta，用于治疗METex14突变的转移性非小细胞肺癌

2020-05-10

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗

2020-02-27

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

2018 AIOM指南：转移性非小细胞肺癌的治疗

2019-07-10

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌

2019-05-05

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

拜耳公布larotrectinib治疗NTRK基因融合阳性转移性非小细胞肺癌患者的亚组分析结果

2019-04-14

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

2019 加拿大共识：渐进性，假进行性和寡转移性非小细胞肺癌

2019-03-30

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点

2019-03-14

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

CLIN CANCER RES：T-DM1治疗HER2过表达转移性非小细胞肺癌

2019-01-22

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

2018 ESMO临床实践指南：转移性非小细胞肺癌的诊断，治疗和随访

2018-10-10

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

美国FDA批准VIZIMPRO用于EGFR突变的转移性非小细胞肺癌的一线治疗

2018-09-30

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

Lancet oncol：ALT-803（IL-15强激动剂）联合nivolumab用于转移性非小细胞肺癌安全性可耐受

2018-04-08

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

ANN ONCOL：反应程度与接受靶向或免疫治疗的转移性非小细胞肺癌患者预后的关系

2017-11-11

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

Front Pharmacol：在铂类治疗的转移性非小细胞肺癌患者中添加中药，能提高患者生活质量

2017-08-13

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

JAMA Oncol：转移性非小细胞肺癌免疫检查点抑制剂、靶向治疗和常规治疗的里程碑分析

2017-06-21

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

2016ESMO临床实践指南——转移性非小细胞肺癌的诊断、治疗和随访发布

2016-09-29

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

招募患者：Nivolumab注射液治疗晚期或转移性非小细胞肺癌的临床试验

2015-12-29

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

招募患者：AZD9291治疗局部晚期或转移性非小细胞肺癌的开放、单臂临床研究

2015-09-11

anan (审核中...)

前往app查看评论内容

#转移性非小细胞肺癌#

Cancer：转移性非小细胞肺癌化疗治疗模式

2015-05-01

科室
- - 订阅+
  - 更多科室
工具
服务